Pharyngitis News and Research

RSS
Cimzia approved in U.S. for rheumatoid arthritis

Cimzia approved in U.S. for rheumatoid arthritis

Seroquel XR supplemental NDA recommended for approval

Seroquel XR supplemental NDA recommended for approval

Mysterious fevers of unknown origin: Could surgery be a cure?

Mysterious fevers of unknown origin: Could surgery be a cure?

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

FDA approves XYZAL (levocetirizine dihydrochloride) for allergies and chronic idiopathic urticaria

FDA approves XYZAL (levocetirizine dihydrochloride) for allergies and chronic idiopathic urticaria

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

Positive results from trial of investigational anti-epilepsy drug Brivaracetam

Modafinil effective treatment for excessive sleepiness

Modafinil effective treatment for excessive sleepiness

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Alphanate approved to treat Von Willebrand disease

Alphanate approved to treat Von Willebrand disease

Antibiotics overprescribed for sore throat

Antibiotics overprescribed for sore throat

Situation-specific policies can reduce antibiotic resistance in hospital

Situation-specific policies can reduce antibiotic resistance in hospital

Antibiotics not effective for many coughs

Antibiotics not effective for many coughs

Antibiotics show little benefit for uncomplicated lower respiratory tract infections

Antibiotics show little benefit for uncomplicated lower respiratory tract infections

Intervention with once-daily budesonide reduces long-term risk and frequency of severe asthma-related events

Intervention with once-daily budesonide reduces long-term risk and frequency of severe asthma-related events

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus